San Diego, CA (PRWEB) September 17, 2013
Histogen, Inc., a regenerative medicine company developing innovative therapies based on the products of cells grown under simulated embryonic conditions, today announced that the United States Patent & Trademark Office has issued patent 8,535,913, entitled “Soluble Composition for Promoting Hair Growth Produced by Hypoxic Culture of Fibroblast Cells”.
The patent, which is the fourth US patent issued to the Company, covers the liquid composition of proteins and cofactors that is secreted by multipotent stem cells through Histogen’s technology process, and the method of administering that composition to stimulate hair growth. Histogen’s Hair Stimulating Complex (HSC), covered by this new patent, is in clinical development as an injectable treatment for male pattern and female diffuse hair loss.
“We are extremely pleased that HSC, and future hair restoration treatments using this technology, are now bolstered by a US patent,” said Dr. Gail K. Naughton, Histogen CEO and Chairman of the Board. “At a time when the industry continues to uncover information about how cell-signaling results in hair growth and maintenance, patent protection for our unique composition of proteins and growth factors is of great benefit to Histogen and its future partners.”
Several factors critical to hair growth such as follistatin, VEGF and KGF, are present in HSC, and their secretion by the cells is stimulated by low oxygen and special culture conditions utilized by Histogen. The conditions under which the cells are manufactured not only upregulates genes associated with hair growth, but induces significantly increased production of these critical factors than seen with traditional culture conditions.
In two Company-sponsored clinical trials, HSC has resulted in statistically significant increases across hair growth parameters, including hair count, density and thickness. In ad
Copyright©2012 Vocus, Inc.
All rights reserved